Senseonics To Participate in Upcoming Institutional Investor Conferences

Senseonics plans investor meetings and a formal presentation at two New York conferences in mid-September 2026.

Rhea-AI Summary

Senseonics (SENS) will participate in two institutional investor conferences in New York in September 2026.

Management will host one-on-one investor meetings at the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference on September 10, 2026. At the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026, management will present at 3:00 pm ET on Monday, September 14, and also hold one-on-one meetings with investors.

Key Terms

continuous glucose monitoring, tetracycline class

2 terms

continuous glucose monitoring medical

"The Eversense Continuous Glucose Monitoring (CGM) Systems"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

tetracycline class medical

"when taking medications of the tetracycline class"

A group of antibiotics that share a common chemical structure and work by blocking bacteria from making proteins they need to grow. Think of them as a family of tools designed to stop many kinds of bacterial infections; some are older, well-known medicines and others are newer derivatives that aim to overcome resistance. Investors follow this class because regulatory approvals, patent status, clinical trial results, and bacterial resistance trends directly affect the commercial value of drugs in development or on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below:

Lake Street 10^th Annual Big Ideas Growth Conference – September 10, 2026 (New York, NY)
Management will host one-on-one meetings with investors at the Lake Street Capital Markets 10^th Annual Big Ideas Growth Conference on Thursday, September 10^th.

H.C. Wainwright 28^th Annual Global Investment Conference – September 14-16, 2026 (New York, NY)
Management will present at 3:00 pm ET and will host one-on-one meetings with investors on Monday, September 14^th.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the design, development and commercialization of glucose monitoring products to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Eversense

The Eversense Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and up to 180 days for Eversense E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense 365 and one time per day after day 21 for Eversense E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

FAQ

What products does Senseonics develop and commercialize?

Senseonics develops and commercializes long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its Eversense 365 and Eversense E3 systems use a small sensor implanted under the skin that communicates with a smart transmitter worn over the sensor, sending glucose data automatically every 5 minutes to a mobile app on the user’s smartphone.

How long can Eversense CGM sensors be used, and who are they for?

The Eversense CGM Systems are indicated for persons with diabetes aged 18 and older. Eversense 365 measures glucose levels for up to 365 days, and Eversense E3 for up to 180 days.